Új vizsgálatok, publikációk, preprintek és pályázatok ezen a célponton, hónapról hónapra.
Vizsgálat
Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D Mutation
2027. jún. 6.· PHASE2_PHASE3 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma
2027. jún. 1.· PHASE1_PHASE2 · RECRUITING· CTGOV
Vizsgálat
TCR1188-ABC Cells in KRAS-mutated Cancers
2026. dec. 1.· PHASE1 · RECRUITING· CTGOV
Publikáció
Development and Validation of an UPLC-QqQ MS/MS Method for the Determination of Daraxonrasib, a New pan-KRAS Inhibitor, in Dog Plasma and Whole Blood and Its Application to Pharmacokinetic Studies.
2026. dec. 1.· Biomedical chromatography : BMC· PUBMED
Vizsgálat
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma
2026. nov. 11.· PHASE1_PHASE2 · SUSPENDED· CTGOV
Publikáció
Toxoplasma gondii GRA16-induced apoptosis in KRAS-mutant colorectal cancer cells is linked to coordinated p53 and PP2A-B55 signaling.
2026. nov. 6.· Parasites, hosts and diseases· PUBMED
Publikáció
Simultaneous LC-MS/MS quantification of four KRAS inhibitors (RMC-6236, RMC-9805, RMC-7977, and MRTX1133) in human plasma: toward therapeutic drug monitoring in pancreatic ductal adenocarcinoma.
2026. nov. 5.· Bioanalysis· PUBMED
Publikáció
CRIP1 Promotes Ovarian Cancer Progression by Mediating the KRAS-USP7 Interaction and Stabilizing KRAS.
2026. nov. 5.· Reproductive sciences (Thousand Oaks, Calif.)· PUBMED
Publikáció
Uncovering KRAS-mutant allele-specific biology and vulnerabilities in non-small cell lung cancer.
2026. nov. 4.· The Biochemical journal· PUBMED
Publikáció
ROCK2 inhibitor belumosudil overcomes resistance to KRAS inhibition in pancreatic cancer models.
2026. nov. 3.· JCI insight· PUBMED
Publikáció
KRAS G12Y Causing a False-Positive KRAS G12C Result With an Indistinguishable PCR Pattern in Lung Adenocarcinoma.
2026. nov. 2.· Respirology case reports· PUBMED
Publikáció
Saturation mutagenesis library screening identifies on-target secondary resistance mutations in KRASG12D-selective inhibitors.
2026. nov. 2.· Cancer letters· PUBMED
Publikáció
EML4-ALK Mediates Resistance to KRASG12C Inhibition and Induces an Oncogenic Dependency by Rewiring Signaling through the Wild-Type RAS Pathway.
2026. nov. 2.· Cancer discovery· PUBMED
Publikáció
Targeting KRAS Codon 13 Mutations Using Direct Combination Approaches in Non-Small Cell Lung Cancer.
2026. nov. 2.· Cancer discovery· PUBMED
Vizsgálat
Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer
2026. nov. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
GFH375 Plus Cetuximab vs Investigator's Choice of Treatment in KRAS G12D-Mutant Refractory Metastatic Colorectal Cancer
2026. nov. 1.· PHASE3 · NOT_YET_RECRUITING· CTGOV
Publikáció
ASO Visual Abstract: KRAS and TP53 Circulating Tumor DNA are Prognostic in Localized Pancreatic Cancer.
2026. nov. 1.· Annals of surgical oncology· PUBMED
Publikáció
Divergent Roles of PIK3C3 in KRAS-Wild-Type and KRAS-Mutant Advanced Colorectal Cancer: Implications for 5-Fluorouracil Sensitivity and Prognosis.
2026. nov. 1.· Cancer medicine· PUBMED
Publikáció
Identification of a Novel KRAS::ETNK1 Fusion Transcript in a Myelodysplastic/Myeloproliferative Overlap Syndrome With Eosinophilia: A Case Report.
2026. nov. 1.· EJHaem· PUBMED
Publikáció
Combination of canagliflozin and adagrasib as a novel targeted therapy for LKB1-KRASG12C co-mutated NSCLC.
2026. nov. 1.· Cancer letters· PUBMED
Vizsgálat
A Study to Evaluate the Safety and Activity of GDC-7035 With Anti-Cancer Therapies in Participants With KRAS G12D-Mutated Unresectable Advanced or Metastatic Colorectal Cancer or Pancreatic Ductal Adenocarcinoma
2026. okt. 31.· PHASE1 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
2026. okt. 31.· PHASE3 · NOT_YET_RECRUITING· CTGOV
Publikáció
KRAS-mutated non-small cell lung cancer (NSCLC) in South India: Real-world genomic landscape, treatment patterns, and outcomes.
2026. okt. 31.· Lung India : official organ of Indian Chest Society· PUBMED
Publikáció
KRAS in pancreatic cancer: from molecular biology to transformative therapeutics.
2026. okt. 30.· Journal of hematology & oncology· PUBMED
Publikáció
Intrinsic resistance to KRAS inhibition: Interfering with interferon.
2026. okt. 29.· Cancer cell· PUBMED
Publikáció
KRASG12D-targeted therapy sensitivity depends on interferon signaling activation in pancreatic cancer.
2026. okt. 29.· Cancer cell· PUBMED
Publikáció
Oncogenic KRAS Suppresses IFNγ Signaling in Tumor Cells.
2026. okt. 28.· Cancer immunology research· PUBMED
Publikáció
Divarasib Bests 1st-Generation KRASG12C Inhibitors.
2026. okt. 27.· Cancer discovery· PUBMED
Publikáció
Tumor-associated Macrophages Promote Adaptive Tolerance in KRAS G12C-mutant Lung Cancer Cells by Secreting TGF-β1.
2026. okt. 27.· Anti-cancer agents in medicinal chemistry· PUBMED
Vizsgálat
MRD Monitoring in Colorectal Cancer Using ctDNA
2026. okt. 26.· NA · RECRUITING· CTGOV